Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2005 Sep-Oct;25(5):3581-4.

Chemokines in human colorectal carcinoma.

Author information

1
University of Freiburg, Department of Surgery, Freiburg, Germany. baier@chir.ukl.uni-freiburg.de

Abstract

BACKGROUND:

Chemokines (CKs) may promote antitumor immunity in cancer, act as tumor growth factors, influence metastatic spreading or angiogenesis. The purpose of this study was to investigate whether CK expression is altered in colorectal carcinomas compared to normal mucosa and to elucidate its possible clinico-pathological implications.

MATERIALS AND METHODS:

The levels of CCL2 (MCP-1), CCL4 (MIP-1beta), CCL5 (RANTES), CXCL 1 (GRO-alpha), CXCL 5 (ENA-78) and CXCL 8 (IL-8) were investigated in 10 colorectal carcinomas and their corresponding normal mucosa by the use of ELISA.

RESULTS:

All CK analyzed, with the exception of CCL5 (RANTES), were expressed at a significantly higher level in malignant tissue.

CONCLUSION:

Therapeutic studies in colon carcinomas should, therefore, focus more on the neutralization of CKs than on their application.

PMID:
16101183
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center